Abstract
Background: Diastolic dysfunction is common in the elderly. Increased myocardial fibrosis, a major determinant of diastolic function, has been observed with advancing age. Spironolactone prevents age‐related increases in myocardial fibrosis in old normotensive rats.
Hypothesis: Spironolactone, via its antifibrotic activity, can improve diastolic function in the elderly with isolated diastolic dysfunction.
Methods: The study was a prospective, double‐blind, randomized, placebo‐controlled trial. Thirty elderly subjects between 60 and 85 years of age with isolated diastolic dysfunction and no contraindications for spironolactone were randomized to 25 mg/day of spironolactone or placebo for 4 months. Mitral E/A and deceleration time, plasma levels of carboxy‐terminal of procollagen type I (PICP), and brain natriuretic peptide (BNP) were measured at baseline and at the end of 4 months. Plasma level of potassium was also monitored to prevent clinically significant hyperkalemia.
Results: There was no serious adverse event or clinically significant hyperkalemia in the spironolactone group. Compared with baseline values, spironolactone significantly improved mitral E/A ratio (0.71 ± 0.08 vs. 0.84 ± 0.19, p=0.025) and deceleration time (285.5 ± 73.1 vs. 230.0 ± 54.7, p = 0.035). There were no significant differences in the magnitude of change in the levels of PICP and BNP between the two treatment groups.
Conclusion: Spironolactone may improve diastolic function in the elderly.
Keywords: diastolic function, aging, spironolactone, fibrosis, clinical trial
Full Text
The Full Text of this article is available as a PDF (182.3 KB).
References
- 1. Kannel WB, Belanger AJ: Epidemiology of heart failure: Am Heart J 1991; 121: 951–957 [DOI] [PubMed] [Google Scholar]
- 2. Kannel WB: Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J 1987; 8 (suppl F): 23–26 [DOI] [PubMed] [Google Scholar]
- 3. Kitzman DW: Diastolic function in the elderly, genesis and diagnostic and therapeutic implications. Cardiol Clin 2000; 18: 597–617 [DOI] [PubMed] [Google Scholar]
- 4. Zannad F, Dousset B, Alla F: Treatment of congestive heart failure, interfering the aldosterone‐cardiac extracellular matrix relationship. Hypertension 2001; 38: 1227–1232 [DOI] [PubMed] [Google Scholar]
- 5. Brilla C, Weber K: Reactive and reparative myocardial fibrosis in arterial hypertension in rats. Cardiovasc Res 1992; 26: 671–677 [DOI] [PubMed] [Google Scholar]
- 6. Young M, Funder J: Determinants of cardiac fibrosis in experimental hyper‐mineralocorticoid states. Am J Physiol 1995; 269: E657–662 [DOI] [PubMed] [Google Scholar]
- 7. Delcayre C, Silvestre JS: Review: Aldosterone and the heart: Towards a physiological function? Cardiovasc Res 1999; 43: 7–12 [DOI] [PubMed] [Google Scholar]
- 8. Brilla C, Matsubara LS, Weber KT: Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A–16A [DOI] [PubMed] [Google Scholar]
- 9. Lijnen P, Petrov V: Antagonism of the renin angiotensin aldosterone system and collagen metabolism in cardiac fibroblasts. Method Find Exp Clin Pharmacol 1999; 21: 215–227 [DOI] [PubMed] [Google Scholar]
- 10. Silvestre J, Heymes C, Oubenaissa A, Robert V, Aupetit‐Faisant B, Carayon A, Swynghedauw B, Delcayre C: Activation of cardiac aldosterone production in rat myocardial infarction: Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694–2701 [DOI] [PubMed] [Google Scholar]
- 11. Lacolley P, Safer ME, Lucet B, Ledudal K, Labat C, Benetos A: Prevention of aortic and cardiac fibrosis by spironolactone on old normotensive rats. J Am Coll Cardiol 2001; 37: 662–667 [DOI] [PubMed] [Google Scholar]
- 12. Sato A, Hayashi M, Saruta T: Relative long‐term effects of spironolactone in conjunction with angiotensin‐converting enzyme inhibitors on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25: 837–842 [DOI] [PubMed] [Google Scholar]
- 13. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH: Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110: 558–565 [DOI] [PubMed] [Google Scholar]
- 14. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–313 [DOI] [PubMed] [Google Scholar]
- 15. Tsutamoto T, Wada A, Maeka K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M: Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228–1233 [DOI] [PubMed] [Google Scholar]
- 16. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago Jl, Gutierrez‐Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Diez J: Serum carboxy‐terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729–1735 [DOI] [PubMed] [Google Scholar]
- 17. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, Diez J: Increased collagen type I synthesis in patients with heart failure of hypertensive origin: Relation to myocardial fibrosis. Circulation 2004; 110: 1263–1268 [DOI] [PubMed] [Google Scholar]
- 18. Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extra‐cellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000; 102: 2700–2706 [DOI] [PubMed] [Google Scholar]